Let me start off with saying I don’t believe we
Post# of 32642
I was in AVXL when they did a RS to uplist, the price went up quickly on Nasdaq, then it was heavily shorted, and it had three or four days in a row that more shares were traded than the company had outstanding. Now AVXL is nothing like FUSZ, they are a biotech company without a product they are selling but have products being tested.
Even though AVXL is different I feel as though a similar thing could happen if FUSZ does a RS without substantial PRs prior or after